1
|
Martín García-Sancho A, Baile M, Rodríguez G, Dlouhy I, Sancho JM, Jarque I, González-Barca E, Salar A, Espeso M, Grande C, Bergua J, Montes-Moreno S, Redondo A, Enjuanes A, Campo E, López-Guillermo A, Caballero D. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO. Br J Haematol 2023; 203:202-211. [PMID: 37485564 DOI: 10.1111/bjh.18989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 06/18/2023] [Accepted: 07/10/2023] [Indexed: 07/25/2023]
Abstract
Diffuse large B-cell lymphoma (DLBCL) patients with relapsed or refractory (RR) disease have poor outcomes with current salvage regimens. We conducted a phase 2 trial to analyse the safety and efficacy of adding lenalidomide to R-ESHAP (LR-ESHAP) in patients with RR DLBCL. Subjects received 3 cycles of lenalidomide 10 mg/day on days 1-14 of every 21-day cycle, in combination with R-ESHAP at standard doses. Responding patients underwent autologous stem-cell transplantation (ASCT). The primary endpoint was the overall response rate (ORR) after 3 cycles. Centralized cell-of-origin (COO) classification was performed. Forty-six patients were included. The ORR after LR-ESHAP was 67% (35% of patients achieved complete remission). Patients with primary refractory disease (n = 26) had significantly worse ORR than patients with non-refractory disease (54% vs. 85%, p = 0.031). No differences in response rates according to the COO were observed. Twenty-eight patients (61%) underwent ASCT. At a median follow-up of 41 months, the estimated 3-year PFS and OS were 42% and 48%, respectively. The most common grade ≥3 adverse events were thrombocytopenia (70% of patients), neutropenia (67%) and anaemia (35%). There were no treatment-related deaths during LR-ESHAP cycles. In conclusion, LR-ESHAP is a feasible salvage regimen with promising efficacy results for patients with RR DLBCL.
Collapse
Affiliation(s)
- A Martín García-Sancho
- Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain
| | - M Baile
- Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain
| | - G Rodríguez
- Hematology Department, Hospital Universitario Virgen del Rocío/Virgen Macarena, Sevilla, Spain
| | - I Dlouhy
- Hematology Department, Hospital Clinic, Barcelona, Spain
| | - J M Sancho
- Hematology Department, Hospital Germans Trias i Pujol/ICO-IJC, Badalona, Spain
| | - I Jarque
- Hematology Department, Hospital Universitari i Plotècnic La Fe, CIBERONC, Valencia, Spain
| | - E González-Barca
- Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de-Barcelona, Barcelona, Spain
| | - A Salar
- Hematology Department, Hospital del Mar, Barcelona, Spain
| | - M Espeso
- Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - C Grande
- Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J Bergua
- Hematology Department, Hospital San Pedro de Alcántara, Cáceres, Spain
| | - S Montes-Moreno
- Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - A Redondo
- Hematology Department, Hospital Virgen del Puerto, Plasencia, Spain
| | - A Enjuanes
- Unidad de Genómica del IDIBAPS, Barcelona, Spain
| | - E Campo
- Pathology Department, Hospital Clinic, Barcelona, Spain
| | | | - D Caballero
- Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain
| |
Collapse
|
2
|
Alvarez-Ortega C, Solorzano C, Barrera A, Toquero J, Martinez-Alday JD, Grande C, Rodriguez A, Garcia-Alberola A, Perez L, Ferrero A, Hernandez J, Cozar R, Cano O, Trucco E, Peinado R. Repeat cryoablation as a redo procedure for atrial fibrillation ablation: Is it a good choice? Europace 2022. [DOI: 10.1093/europace/euac053.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Medtronic Inc.
Introduction
Catheter ablation of atrial fibrillation, both cryoablation and radiofrequency pulmonary vein isolation, have demonstrated to be safe and effective techniques for treating symptomatic atrial fibrillation as a first procedure. However, about one in three patients may face a redo procedure due to AF recurrence. The most suitable technique for redo is unknown.
Purpose
The aim of this study is to assess the efficacy of cryoballoon AF ablation as a redo technique in patients with prior cryoballoon or radiofrequency AF ablation.
Methods
We analyzed a nation-wide real-world cryoablation registry (RECABA) and compared patients who were referred for a first cryoballoon AF ablation procedure with those who had previously undergone cryoballoon or radiofrequency pulmonary vein isolation. The primary endpoint was AF recurrence during the first year after a 3-month blanking period. We performed survival analysis and built univariate and multivariate cox regression models.
Results
From 1742 patients, 1625 had a 12-month follow-up visit. 1551 (95.45%) underwent a first cryoballoon ablation, whereas 33 (2.03%) had a previous CB ablation performed and 41 (2.52%) a previous RF ablation.
Mean age was 58.6 ±10.4 years and 511 (31.5%) were women. 463 (28.5%) had persistent atrial fibrillation and there were no major clinical differences between groups.
Prior-CB group had a higher share of veins without electrogram visualization, with a median of 100% (IQR 75%-100%), compared to prior-RF group (median 67%, IQR 25%-75%) and first procedure group (median 25%, IQR 0%-50%). Kruskal-Wallis test Chi2=54.35, p<0.0001.
12-month Kaplan–Meier estimate of freedom from AF recurrence after the blanking period was 78.5% (95% CI 76.2% - 80.7%) in the first procedure group, 61.0% (95% CI 41.4% - 75.8%) in the prior-CB and 89.2% (95% CI 73.6% - 95.9%) in the prior-RF group. Log-rank test Chi2=17.49, p<0.0001.
Multivariate cox regression analysis pointed female sex, persistent AF, and prior-CB ablation as independent predictors of AF recurrence. The adjusted HR for AF recurrence of prior-CB ablation vs first-CB ablation was 3.13 (95% CI 1.82 -5.40) and for prior-RF vs first CB-ablation was 1.01 (95% CI 0.51 – 1.97).
Conclusion
Repeat cryoballoon AF ablation shows higher rates of AF recurrences compared to first CB procedures or after prior RF ablation. These data suggest that patients with AF recurrence after CB-ablation have worse arrhythmic outcomes and may benefit from other ablation techniques after a recurrence.
Collapse
Affiliation(s)
| | - C Solorzano
- University Hospital La Paz, Cardiology, Madrid, Spain
| | - A Barrera
- UNIVERSITY HOSPITAL VIRGEN DE LA VICTORIA, Cardiology, Malaga, Spain
| | - J Toquero
- University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain
| | | | - C Grande
- Hospital Universitari Son Espases, Cardiology, Palma de Mallorca, Spain
| | - A Rodriguez
- INCANIS Hospital Universitario de Canarias, Cardiology, La Laguna, Spain
| | | | - L Perez
- CHUAC, Cardiology, A Coruna, Spain
| | - A Ferrero
- University Clinical Hospital Valencia, Cardiology, Valencia, Spain
| | - J Hernandez
- University Hospital Nuestra Se?ora de Candelaria, Cardiology, Santa Cruz de Tenerife, Spain
| | - R Cozar
- UNIVERSITY HOSPITAL VIRGEN MACARENA, Cardiology, Seville, Spain
| | - O Cano
- University Hospital La Fe, Cardiology, Valencia, Spain
| | - E Trucco
- University Hospital de Girona Dr. Josep Trueta, Cardiology, Girona, Spain
| | - R Peinado
- University Hospital La Paz, Cardiology, Madrid, Spain
| |
Collapse
|
3
|
Búa BR, Jiménez‐Ubieto A, Blanco JJS, Abrisqueta P, Gutiérrez A, Ramírez‐Páyer Á, Giné E, Etxetxipia IZ, Terol MJ, Cruz FDL, Andreu R, Ramírez M, Fuente ADL, Viguria M, Peñarrubia M, Grande C, Montes‐Moreno S, Barrigón MDC, García‐Sancho AM. UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.94_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- B. Rey Búa
- Hospital Universitario de Salamanca and IBSAL Hematology Department Salamanca Spain
| | | | | | - P. Abrisqueta
- Hospital Vall d’Hebron Hematology Department Barcelona Spain
| | - A. Gutiérrez
- H. Son Espases Hematology Department Palma de Mallorca Spain
| | | | - E. Giné
- H. Clinic de Barcelona Hematology Department Barcelona Spain
| | - I. Zeberio Etxetxipia
- Hospital Universitario de Donostia Hematology Department Donostia‐San Sebastian Spain
| | | | - F. de la Cruz
- Hospital Virgen del Rocio Hematology Department Sevilla Spain
| | - R. Andreu
- Hospital la Fe Hematology Department Valencica Spain
| | - M. Ramírez
- H. Especialidades Jerez de la Frontera Hematology Department Jerez Spain
| | | | - M. Viguria
- Complejo Hospitalario de Navarra Hematology Department Pamplona Spain
| | - M. Peñarrubia
- Hospital Clínico Universitario de Valladolid Hematology Department Valladolid Spain
| | - C. Grande
- Hospital 12 de Octubre Hematology Department Madrid Spain
| | - S. Montes‐Moreno
- H. Universitario Marqués de Valdecilla Pathology Department Santander Spain
| | | | | |
Collapse
|
4
|
Palacios Rubio J, Grande C, Canadas-Godoy V, Perez-Castellano N, Exposito-Pineda C. P2880Incidence and clinical relevance of oversensing due to extracardiac signals in subcutaneous implantable cardiac defibrillator (S-ICD). Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
S-ICD is an ICD system completely extrathoracic, composed of a generator in a left infra-axillary position and a parasternal lead. Arrhythmia detection is done by analyzing extracardiac signals registered in a dipole that is several centimeters in length, larger than in a transvenous ICD. Hence, it could potentially be more susceptible to external interference (eg. myopotentials or electromagnetic noise).
Purpose
To assess real-world incidence and clinical relevance of oversensing due to extracardiac signals (OES) in S-ICD.
Methods
Retrospective review of medical reports and remote monitoring system in two Spanish hospitals. Events were assessed by EHRA-certified specialists in cardiac devices. Differences in patients with OES were sought by univariate analysis using parametric or non-parametric methods according to sample characteristics.
Results
117 patients since October 2014 were analyzed. 88 (75,2%) men, age at implant 49,1±13,8 years. Implants were indicated mainly in primary prevention (72; 61,5%), due to ischemic cardiomyopathy (52; 44,4%), NYHA functional class I-II (107; 91,5%). 24 (20,5%) had intraventricular conduction disorders (9 right bundle branch, 2 left, 13 delayed intraventricular conduction). Electrodes implanted mostly left parasternal (107; 91,5%). On implant, gain ×1 in 90 (96,7% cases with data registered; 24 cases not registered), SmartPass activated in every device with such tool available.
Patients were followed-up for 1,9±1,2 years (maximum 4,2). 4 (3,4%) received appropriate shocks, 10 (8,5%) inappropriate: 3 OES, 3 T-wave oversensing, 3 voltage decrease (leading to SmartPass deactivation), 1 lead dysfunction. In 8 cases OES was identified (incidence 3,7 /100 patients/year): in 3 (37,5%) cases inappropriate shocks were delivered. OES occurred 1,9 (interquartile range, IQR, 0,9–2,9) years after implant. No differences in OES were found depending on sex, indication, S-ICD or lead model, lead position, intraventricular conduction disorders, detection vector at implant, number of suitable vectors at screening, tachycardia detection rate or SmartPass automatic deactivation during follow-up
In 5 cases, a cause for OES was identified: 4 myopotentials, 1 interference from electric engine. Cases were managed by changing sensing vector (3), increasing tachycardia detection rate (2), watchful waiting (2, OES source unidentified) or providing instructions to the patient (1). No OES recurrence after 0,8 years (IQR 0,6–1,1).
Example of OES
Conclusions
S-ICD has an incidence of OES of 3,7 cases /100 patients/year. OES can be successfully managed with a conservative approach.
Collapse
Affiliation(s)
- J Palacios Rubio
- University Hospital Son Espases, Cardiology, Palma de Mallorca, Spain
| | - C Grande
- University Hospital Son Espases, Cardiology, Palma de Mallorca, Spain
| | - V Canadas-Godoy
- Hospital Clinic San Carlos, Cardiovascular Institute, Madrid, Spain
| | | | - C Exposito-Pineda
- University Hospital Son Espases, Cardiology, Palma de Mallorca, Spain
| |
Collapse
|
5
|
Baile M, Barrena S, Sancho J, Grande C, Fernández R, Batlle A, Peñarrubia M, Peñalver F, Hernández-Rivas J, Guinea M, Pérez J, García-Álvarez M, Alcoceba M, Vidriales B, Orfao A, Martín A. EVALUATION OF BONE MARROW INFILTRATION BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: SUB-STUDY OF A PHASE 2 GELTAMO CLINICAL TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.26_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Baile
- Hematology Department; Hospital Universitario de Salamanca / IBSAL; Salamanca Spain
| | - S. Barrena
- Cytometry (NUCLEUS); Cancer Research Center and University of Salamanca (IBMCC-USAL-CISC); Salamanca Spain
| | - J. Sancho
- Hematology; Hospital Germans Trias i Pujol / ICO-IJC; Barcelona Spain
| | - C. Grande
- Hematology; Hospital Universitario 12 de Octubre; Madrid Spain
| | | | - A. Batlle
- Hematology; Hospital Universitario Marqués de Valdecilla; Santander Spain
| | - M. Peñarrubia
- Hematology; Hospital Clínico de Valladolid; Valladolid Spain
| | - F. Peñalver
- Hematology; Hospital Universitario Fundación de Alcorcón; Madrid Spain
| | | | - M. Guinea
- Hematology; Hospital Universitario de Araba; Vitoria-Gasteiz Spain
| | - J. Pérez
- Hematology Department; Hospital Universitario de Salamanca / IBSAL; Salamanca Spain
| | - M. García-Álvarez
- Hematology Department; Hospital Universitario de Salamanca / IBSAL; Salamanca Spain
| | - M. Alcoceba
- Hematology Department; Hospital Universitario de Salamanca / IBSAL; Salamanca Spain
| | - B. Vidriales
- Hematology Department; Hospital Universitario de Salamanca / IBSAL; Salamanca Spain
| | - A. Orfao
- Cytometry (NUCLEUS); Cancer Research Center and University of Salamanca (IBMCC-USAL-CISC); Salamanca Spain
| | - A. Martín
- Hematology Department; Hospital Universitario de Salamanca / IBSAL; Salamanca Spain
| |
Collapse
|
6
|
Martinez Calle N, Diaz De Cerio A, Pena E, Garcia Muñoz R, Panizo A, Feliu J, Giraldo P, Rodriguez M, Grande C, Olave T, Andrade-Campos M, Bandres E, Nuñez J, Inoges S, Panizo C. RESULTS OF PHASE II STUDY OF COMBINED IMMUNOTHERAPY WITH RITUXIMAB PLUS LYMPHOKINE-ACTIVATED KILLER CELLS AS MAINTENANCE IN FOLLICULAR LYMPHOMA PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.192_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Martinez Calle
- Hematology; Nottingham University Hospitals NHS Trust; Nottingham United Kingdom
| | | | - E. Pena
- Hematology; University Clinic Of Navarre; Pamplona Spain
| | | | - A. Panizo
- Pathology; Hospital Complex of Navarre, Limphoproliferative Group, Health Research Institute Navarre (IDISNA); Pamplona Spain
| | - J. Feliu
- Hematology; Hospital San Pedro; Logroño Spain
| | - P. Giraldo
- Hematology; Instituto Aragonés de Ciencias de la Salud CIBERER; Zaragoza Spain
| | - M. Rodriguez
- Hematology; Hospital Complex of Navarre; Pamplona Spain
| | - C. Grande
- Hematology; Hospital 12 De Octubre; Madrid Spain
| | - T. Olave
- Hematology; Hospital Clinico Universitario Lozano Blesa; Zaragoza Spain
| | | | - E. Bandres
- Hematology; Hospital Complex of Navarre; Pamplona Spain
| | - J. Nuñez
- Research support service; University Clinic of Navarre; Pamplona Spain
| | - S. Inoges
- Hematology; University Clinic Of Navarre; Pamplona Spain
| | - C. Panizo
- Hematology; University Clinic Of Navarre; Pamplona Spain
| |
Collapse
|
7
|
Chimenti C, Verardo R, Grande C, Russo MA, Frustaci A. 2352Hypertrophy of unaffected cardiomyocytes concurs to severity of cardiomyopathy in female patients with Fabry disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.2352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C Chimenti
- Sapienza University of Rome, Rome, Italy
| | - R Verardo
- Sapienza University of Rome, Rome, Italy
| | - C Grande
- Sapienza University of Rome, Rome, Italy
| | - M A Russo
- San Raffaele Pisana Hospital IRCCS, Rome, Italy
| | - A Frustaci
- Sapienza University of Rome, Rome, Italy
| |
Collapse
|
8
|
Frustaci A, Verardo R, Grande C, Caldarulo M, Galea N, Francone M, Miraldi F, Chimenti C. P682Pathology of conduction tissue in cardiac amyloid: correlation with arrhythmic manifestations. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A Frustaci
- Sapienza University, Department of Cardiovascular, Respiratory, Nefrologic and Geriatric Sciences, Rome, Italy
| | - R Verardo
- INMI-IRCCS “Lazzaro Spallanzani”, Laboratory of Cellular and Molecular Cardiology, Rome, Italy
| | - C Grande
- INMI-IRCCS “Lazzaro Spallanzani”, Laboratory of Cellular and Molecular Cardiology, Rome, Italy
| | - M Caldarulo
- INMI-IRCCS “Lazzaro Spallanzani”, Laboratory of Cellular and Molecular Cardiology, Rome, Italy
| | - N Galea
- La Sapienza University, Radiology, Rome, Italy
| | - M Francone
- La Sapienza University, Radiology, Rome, Italy
| | - F Miraldi
- Sapienza University, Department of Cardiovascular, Respiratory, Nefrologic and Geriatric Sciences, Rome, Italy
| | - C Chimenti
- Sapienza University, Department of Cardiovascular, Respiratory, Nefrologic and Geriatric Sciences, Rome, Italy
| |
Collapse
|
9
|
Brose M, Shenoy S, Bhat N, Harlacker A, Yurtal R, Posey Z, Torrente D, Grande C, Squillante C, Troxel A, Yarchoan M. A Phase 2 Trial of Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Carcinoma in the First-Line Setting. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2017.12.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Vezzulli L, Stagnaro L, Grande C, Tassistro G, Canesi L, Pruzzo C. Comparative 16SrDNA Gene-Based Microbiota Profiles of the Pacific Oyster (Crassostrea gigas) and the Mediterranean Mussel (Mytilus galloprovincialis) from a Shellfish Farm (Ligurian Sea, Italy). Microb Ecol 2018; 75:495-504. [PMID: 28803409 DOI: 10.1007/s00248-017-1051-6] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Accepted: 07/27/2017] [Indexed: 06/07/2023]
Abstract
The pacific oyster Crassostrea gigas and the Mediterranean mussel Mytilus galloprovincialis are two widely farmed bivalve species which show contrasting behaviour in relation to microbial diseases, with C. gigas being more susceptible and M. galloprovincialis being generally resistant. In a recent study, we showed that different susceptibility to infection exhibited by these two bivalve species may depend on their different capability to kill invading pathogens (e.g., Vibrio spp.) through the action of haemolymph components. Specific microbial-host interactions may also impact bivalve microbiome structure and further influence susceptibility/resistance to microbial diseases. To further investigate this concept, a comparative study of haemolymph and digestive gland 16SrDNA gene-based bacterial microbiota profiles in C. gigas and M. galloprovincialis co-cultivated at the same aquaculture site was carried out using pyrosequencing. Bacterial communities associated with bivalve tissues (hemolymph and digestive gland) were significantly different from those of seawater, and were dominated by relatively few genera such as Vibrio and Pseudoalteromonas. In general, Vibrio accounted for a larger fraction of the microbiota in C. gigas (on average 1.7-fold in the haemolymph) compared to M. galloprovincialis, suggesting that C. gigas may provide better conditions for survival for these bacteria, including potential pathogenic species such as V. aestuarianus. Vibrios appeared to be important members of C. gigas and M. galloprovincialis microbiota and might play a contrasting role in health and disease of bivalve species. Accordingly, microbiome analyses performed on bivalve specimens subjected to commercial depuration highlighted the ineffectiveness of such practice in removing Vibrio species from bivalve tissues.
Collapse
Affiliation(s)
- Luigi Vezzulli
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy.
| | - L Stagnaro
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| | - C Grande
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| | - G Tassistro
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| | - L Canesi
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| | - C Pruzzo
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| |
Collapse
|
11
|
Alonso-Alconada L, Barbazan J, Candamio S, Falco JL, Anton C, Martin-Saborido C, Fuster G, Sampedro M, Grande C, Lado R, Sampietro-Colom L, Crego E, Figueiras S, Leon-Mateos L, Lopez-Lopez R, Abal M. PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system. Clin Transl Oncol 2017; 20:630-638. [PMID: 29058262 DOI: 10.1007/s12094-017-1760-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 09/30/2017] [Indexed: 12/17/2022]
Abstract
PURPOSE Management of metastatic disease in oncology includes monitoring of therapy response principally by imaging techniques like CT scan. In addition to some limitations, the irruption of liquid biopsy and its application in personalized medicine has encouraged the development of more efficient technologies for prognosis and follow-up of patients in advanced disease. METHODS PrediCTC constitutes a panel of genes for the assessment of circulating tumor cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency compared to CT scan for the evaluation of early therapy response in a multicenter prospective study. In this work, we designed and developed a technology transfer strategy to define the market opportunity for an eventual implementation of PrediCTC in the clinical practice. RESULTS This included the definition of the regulatory framework, the analysis of the regulatory roadmap needed for CE mark, a benchmarking study, the design of a product development strategy, a revision of intellectual property, a cost-effectiveness study and an expert panel consultation. CONCLUSION The definition and analysis of an appropriate technology transfer strategy and the correct balance among regulatory, financial and technical determinants are critical for the transformation of a promising technology into a viable technology, and for the decision of implementing liquid biopsy in the monitoring of therapy response in advanced disease.
Collapse
Affiliation(s)
- L Alonso-Alconada
- Translational Medical Oncology, CIBERONC, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain
| | - J Barbazan
- Translational Medical Oncology, CIBERONC, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain
| | - S Candamio
- Translational Medical Oncology, CIBERONC, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain
| | - J L Falco
- Antares Consulting, Barcelona, Spain
| | - C Anton
- UETeS, Universidad Francisco de Vitoria, Madrid, Spain
| | | | | | - M Sampedro
- Department of Innovation and Transfer, Ramon Dominguez Foundation, Santiago de Compostela, Spain
| | - C Grande
- Medical and Health Technology Innovation Platform (ITEMAS), Galician Network, Santiago de Compostela, Spain
| | - R Lado
- Medical and Health Technology Innovation Platform (ITEMAS), Galician Network, Santiago de Compostela, Spain
| | - L Sampietro-Colom
- Health Technology Assessment Unit, Clinic Hospital, Barcelona, Spain
| | - E Crego
- EFT Consulting, Santiago de Compostela, Spain
| | - S Figueiras
- Health Knowledge Agency (ACIS), Galician Health System (SERGAS), Santiago de Compostela, Spain
| | - L Leon-Mateos
- Health Knowledge Agency (ACIS), Galician Health System (SERGAS), Santiago de Compostela, Spain
| | - R Lopez-Lopez
- Translational Medical Oncology, CIBERONC, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain
| | - M Abal
- Translational Medical Oncology, CIBERONC, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain.
| |
Collapse
|
12
|
Frustaci A, Verardo R, Grande C, Galea N, Carbone I, Alfarano M, Russo M, Chimenti C. 4784Immune-mediated myocardial inflammation in Fabry Disease cardiomyopathy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.4784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Gonzalez-Barca E, Carrillo E, Grande C, Martín A, Montes-Moreno S, Coronado M, Mercadal S, Roncero J, Perez De Oteyza J, Nicolas C, Rodriguez-Salazar M, Sancho J, Palomera L, Lopez J, Albo C, Peñalver F, Hernandez J, Lopez-Guillermo A, Ramirez M, Jarque I, Bargay J, Canales M, Conde E, Caballero D. PHASE 2 RANDOMIZED TRIAL COMPARING STANDARD RCHOP VERSUS BRCAP AS FIRST LINE TREATMENT IN YOUNG PATIENTS WITH HIGH-RISK DLBCL. A STUDY FROM SPANISH GROUP GELTAMO. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_49] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- E. Gonzalez-Barca
- Hematology; Instituto Catalan De Oncologia-L'Hospitalet; Barcelona Spain
| | - E. Carrillo
- Hematology; H. Virgen Del Rocio; Sevilla Spain
| | - C. Grande
- Hematology, H. 12 De Octubre; Madrid Spain
| | - A. Martín
- Hematology; Complejo Hospitalario De Salamanca; Salamanca Spain
| | | | - M. Coronado
- Nuclear Medicine, H. U. La Paz; Madrid Spain
| | - S. Mercadal
- Hematology; Instituto Catalan De Oncologia-L'Hospitalet; Barcelona Spain
| | - J.M. Roncero
- Hematology; ICO Girona (H.U. Dr. Josep Trueta); Girona Spain
| | | | - C. Nicolas
- Hematology; H. U. Central De Asturias; Oviedo Spain
| | | | - J.M. Sancho
- Hematology; Ico Badalona (H. Germans Trias I Pujol); Barcelona Spain
| | - L. Palomera
- Hematology, H. C. U. Lozano Blesa; Zaragoza Spain
| | - J. Lopez
- Hematology, H. U. Ramón Y Cajal; Madrid Spain
| | - C. Albo
- Hematology, C.H.U De Vigo; Pontevedra Spain
| | | | | | | | - M.J. Ramirez
- Hematology, H. De Jerez, Jerez De La Frontera; Spain
| | - I. Jarque
- Hematology, H. U. Politècnic La Fe; Valencia Spain
| | - J. Bargay
- Hematology, H. Son Llàtzer; Palma Spain
| | | | - E. Conde
- Hematology, H. U. Marqués De Valdecilla; Santander Spain
| | - D. Caballero
- Hematology, H. U. Marqués De Valdecilla; Santander Spain
| |
Collapse
|
14
|
Jiménez Ubieto A, Grande C, Caballero D, Yañez L, Novelli S, Hernández-Garcia M, Manzanares M, Arranz R, Ferreiro J, Bobillo S, Mercadal S, Galego A, López-Jiménez J, Moraleda J, Vallejo C, Albo C, Pérez-Ceballos E, Marrero C, Magnano L, Palomera L, Jarque I, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta J. AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGATE THE NEGATIVE PROGNOSTIC EFFECT OF EARLY RELAPSE AFTER CHEMO OR INMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_85] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - C. Grande
- Hematology; Hospital 12 de Octubre; Madrid Spain
| | - D. Caballero
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Yañez
- Hematology; Hospital Universitario Marqués de Valdecilla; Santander Spain
| | - S. Novelli
- Hematology; Hospital Universitario Sant Pau; Barcelona Spain
| | | | - M. Manzanares
- Hematology; Hospital Universitario de Jerez; Jerez Spain
| | - R. Arranz
- Hematology; Hospital Universitario La Princesa; Madrid Spain
| | - J. Ferreiro
- Hematology; Hospital Universitario Donostia-Aránzazu; San Sebastián Spain
| | - S. Bobillo
- Hematology; Hospital Universitario Vall de Hebrón; Barcelona Barcelona Spain
| | - S. Mercadal
- Hematology; Hospital Universitario de Bellvitge, l'Hospitalet de Llobregat; Spain
| | - A. Galego
- Hematology; Hospital Universitario A Coruña, A Coruña; Spain
| | - J. López-Jiménez
- Hematology; Hospital Universitario Ramón y Cajal, Madrid; Madrid Spain
| | - J. Moraleda
- Hematology; Hospital Universitario Virgen de la Arriaxaca, El Palmar; Murcia Spain
| | - C. Vallejo
- Hematology; Hospital Central de Asturias, Asturias; Oviedo Spain
| | - C. Albo
- Hematology; Hospital Universitario de Vigo; Vigo Spain
| | - E. Pérez-Ceballos
- Hematology; Hospital Universitario Morales de Messeguer; Murcia Spain
| | - C. Marrero
- Hematology; Hospital Universitario Nuestra Señora de La Candelaria, Tenerife, Santa Cruz de Tenerife; Spain
| | - L. Magnano
- Hematology; Hospital Clinic de Barcelona; Barcelona Spain
| | - L. Palomera
- Hematology; Hospital Clínico Universitario Lozano Blesa; Zaragoza Spain
| | - I. Jarque
- Hematology; Hospital Universitario La Fe; València Spain
| | - A. Martín
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - E. Coria
- Hematology; Hospital Clínico San Carlos; Madrid Spain
| | | | - A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | - J. Lahuerta
- Hematology; Hospital 12 de Octubre; Madrid Spain
| |
Collapse
|
15
|
Sancho J, Gual F, Fernández-Álvarez R, González-García E, Grande C, Gutiérrez N, Peñarrubia M, Batlle-López A, González-Barca E, Guinea J, Gimeno E, Peñalver F, Fuertes M, Gayoso J, Hernández-Rivas J, Moraleda J, García O, Martín A. R-COMP VS R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Sancho
- Hematology; ICO-IJC-Hospital Germans Trias i Pujol; Badalona Spain
| | - F. Gual
- Cardiology; Hospital Germans Trias i Pujol; Badalona Spain
| | | | | | - C. Grande
- Hematology; Hospital 12 de Octubre; Madrid Spain
| | - N. Gutiérrez
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - M. Peñarrubia
- Hematology; Hospital Clínico Universitario de Valladolid; Valladolid Spain
| | | | - E. González-Barca
- Hematology; ICO-Hospital Durán i Reynals, Hospitalet de Llobregat; Spain
| | - J. Guinea
- Hematology; Ho'spital Universitario de araba; Vitoria Spain
| | - E. Gimeno
- Hematology; Hospital del Mar; Barcelona Spain
| | - F. Peñalver
- Hematology; Hospital Universitario Fundación de Alcorcón; Alcorcón Spain
| | - M. Fuertes
- Hematology; Hospital Clínico Universitario Lozano Blesa; Zaragoza Spain
| | - J. Gayoso
- Hematology; Hospital Gregorio Marañón; Madrid Spain
| | | | - J. Moraleda
- Hematology; Hospital Virgen de la Arrixaca; Murcia Spain
| | - O. García
- Hematology; ICO-IJC-Hospital Germans Trias i Pujol; Badalona Spain
| | - A. Martín
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| |
Collapse
|
16
|
Cabrero M, Lopez-Corral L, de la Cruz F, Jarque I, Valcarcel D, Perez-Lopez E, Martin A, Sanchez-Guijo F, Grande C, Martin-Calvo M, Martin A, Caballero D. Results of a prospective phase II trial with ofatumumab as part of reduced intensity conditioning regimen in high-risk non-Hodgkin B lymphoma patients: A GELTAMO trial. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Cabrero
- Hematology; Salamanca University Hospital; Salamanca Spain
| | | | - F. de la Cruz
- Hematology; Virgen del Rocio University Hospital; Sevilla Spain
| | - I. Jarque
- Hematology; La Fe University Hospital; Valencia Spain
| | - D. Valcarcel
- Hematology; Hospital Vall d'Hebron; Barcelona Spain
| | - E. Perez-Lopez
- Hematology; Salamanca University Hospital; Salamanca Spain
| | - A. Martin
- Hematology; Salamanca University Hospital; Salamanca Spain
| | | | - C. Grande
- Hematology; 12 de Octubre University Hospital; Madrid Spain
| | | | - A. Martin
- Hematology; Salamanca University Hospital; Salamanca Spain
| | - D. Caballero
- Hematology; Salamanca University Hospital; Salamanca Spain
| |
Collapse
|
17
|
Martín A, Baile M, Rodríguez G, Dlouhy I, Sancho J, Jarque I, González-Barca E, Salar A, Espeso M, Grande C, Bergua J, Montes-Moreno S, López-Guillermo A, Campo E, Caballero D. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from the Spanish group GELTAMO. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Martín
- Hematology; Hospital Universitario de Salamanca and IBSAL; Salamanca Spain
| | - M. Baile
- Hematology; Hospital Universitario de Salamanca and IBSAL; Salamanca Spain
| | - G. Rodríguez
- Hematology; UGC HH.UU. Virgen del Rocío / Virgen Macarena; Sevilla Spain
| | - I. Dlouhy
- Hematology; Hospital Clinic; Barcelona Spain
| | - J.M. Sancho
- Hematology; Hospital Germans Trias i Pujol / ICO-IJC, Barcelona; Badalona Spain
| | - I. Jarque
- Hematology; Hospital Universitario La Fe; Valencia Spain
| | - E. González-Barca
- Hematology; Hospital Duran i Reynals / ICO-IDIBELL, Hospitalet de Llobregat; Barcelona Spain
| | - A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | - M. Espeso
- Hematology; Hospital Regional Universitario de Málaga; Málaga Spain
| | - C. Grande
- Hematology; Hospital Universitario 12 de Octubre; Madrid Spain
| | - J. Bergua
- Hematology; Hospital San Pedro de Alcántara; Cáceres Spain
| | - S. Montes-Moreno
- Pathology; Hospital Universitario Marqués de Valdecilla; Santander Spain
| | | | - E. Campo
- Pathology; Hospital Clinic; Barcelona Spain
| | - D. Caballero
- Hematology; Hospital Universitario de Salamanca and IBSAL; Salamanca Spain
| |
Collapse
|
18
|
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello J, Sancho J, Tomás J, Rodriguez M, Peñalver F, Palomera L, Grande C, Sánchez-Blanco J, Arranz R, Conde E, Garcia M, García J, Caballero D, Montalbán C. LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | | | - C. Panizo
- Hematology; Clinica Universitaria Navarra; Pamplona Spain
| | - C. Nicolás
- Hematology; Hospital Central de Asturias; Oviedo Spain
| | - J. Bargay
- Hematology; Hospital Son Llatzer; Palma Mallorca Spain
| | | | - M. Canales
- Hematology; Hospital La Paz; Madrid Spain
| | - J. Bello
- Hematology; Hospital de Santiago Compostela; Santiago de Compostela Spain
| | - J. Sancho
- Hematology; ICO Badalona; Badalona Spain
| | - J. Tomás
- Hematology; MD Anderson Cancer Center; Madrid Spain
| | - M. Rodriguez
- Hematology; Hospital U de Canarias; Tenerife Spain
| | | | - L. Palomera
- Hematology; Hospital Clínico Lozano Blesa; Zaragoza Spain
| | - C. Grande
- Hematology; Hospital 12 de Octubre; Madrid Spain
| | | | - R. Arranz
- Hematology; Hospital de la Princesa; Madrid Spain
| | - E. Conde
- Hematology; Hospital Marqués de Valdecilla; Santander Spain
| | - M. Garcia
- Hematology; Hospital del Mar; Barcelona Spain
| | - J.F. García
- Hematology; MD Anderson Cancer Center; Madrid Spain
| | - D. Caballero
- Hematology; Hospital de Salamanca; Salamanca Spain
| | - C. Montalbán
- Hematology; MD Anderson Cancer Center; Madrid Spain
| |
Collapse
|
19
|
Vezzulli L, Grande C, Tassistro G, Brettar I, Höfle MG, Pereira RPA, Mushi D, Pallavicini A, Vassallo P, Pruzzo C. Whole-Genome Enrichment Provides Deep Insights into Vibrio cholerae Metagenome from an African River. Microb Ecol 2017; 73:734-738. [PMID: 27888291 DOI: 10.1007/s00248-016-0902-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Accepted: 11/16/2016] [Indexed: 06/06/2023]
Abstract
The detection and typing of Vibrio cholerae in natural aquatic environments encounter major methodological challenges related to the fact that the bacterium is often present in environmental matrices at very low abundance in nonculturable state. This study applied, for the first time to our knowledge, a whole-genome enrichment (WGE) and next-generation sequencing (NGS) approach for direct genotyping and metagenomic analysis of low abundant V. cholerae DNA (<50 genome unit/L) from natural water collected in the Morogoro river (Tanzania). The protocol is based on the use of biotinylated RNA baits for target enrichment of V. cholerae metagenomic DNA via hybridization. An enriched V. cholerae metagenome library was generated and sequenced on an Illumina MiSeq platform. Up to 1.8 × 107 bp (4.5× mean read depth) were found to map against V. cholerae reference genome sequences representing an increase of about 2500 times in target DNA coverage compared to theoretical calculations of performance for shotgun metagenomics. Analysis of metagenomic data revealed the presence of several V. cholerae virulence and virulence associated genes in river water including major virulence regions (e.g. CTX prophage and Vibrio pathogenicity island-1) and genetic markers of epidemic strains (e.g. O1-antigen biosynthesis gene cluster) that were not detectable by standard culture and molecular techniques. Overall, besides providing a powerful tool for direct genotyping of V. cholerae in complex environmental matrices, this study provides a 'proof of concept' on the methodological gap that might currently preclude a more comprehensive understanding of toxigenic V. cholerae emergence from natural aquatic environments.
Collapse
Affiliation(s)
- L Vezzulli
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy.
| | - C Grande
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| | - G Tassistro
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| | - I Brettar
- Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - M G Höfle
- Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - R P A Pereira
- Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - D Mushi
- Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - A Pallavicini
- Department of Life Sciences, University of Trieste, Trieste, Italy
| | - P Vassallo
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| | - C Pruzzo
- Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy
| |
Collapse
|
20
|
Dick WF, Baskett PJF, Grande C, Delooz H, Kloeck W, Lackner C, Lipp M, Mauritz W, Nerlich M, Nicholl J, Nolan J, Oakley P, Parr M, Seekamp A, Soreide E, Steen PA, van Camp L, Wolcke B, Yates D. Recommendations for uniform reporting of data following major trauma - the Utstein style. Trauma 2016. [DOI: 10.1177/146040860000200105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Martins Fernandes S, Badano L, Garcia Campos A, Erdei T, Mehdipoor G, Hanboly N, Michalski BW, Vriz O, Mo VY, Le TT, Ribeiro JM, Ternacle J, Yurdakul SELEN, Shetye A, Stoebe S, Lisowska A, Chinali M, Orabona M, Contaldi C, De La Chica JA, Codolosa JN, Trzcinski P, Prado Diaz S, Morales Portano JD, Ha SJ, Valente F, Joseph G, Valente F, Scali MC, Cordeiro F, Duchateau N, Fabris E, Costantino MF, Cho IJ, Goublaire C, Lam W, Galli E, Kim KH, Mariani M, Malev E, Zuercher F, Tang Z, Cimino S, Mahia P, De La Chica JA, Petrovic J, Ciobotaru V, Remsey- Semmelweiss E, Kogoj P, Guerreiro S, Saxena A, Mozenska O, Pontone G, Macaya Ten F, Caballero L, Avegliano G, Halmai L, Reis L, Trifunovic D, Gospodinova M, Makavos G, D'ascenzi F, Dantas Tavares De Melo M, Bonapace S, Kulkarni A, Cameli M, Ingvarsson A, Driessen MMP, Tufekcioglu O, Radulescu D, Barac A, Cioffi G, Almeida Morais L, Ledakowicz-Polak A, Portugal G, Naksuk N, Parato VM, Kovalova S, Cherubini A, Corrado G, Malev E, Wierzbowska-Drabik K, Lesevic H, Laredj N, Pieles GE, Generati G, Van Zalen JJ, Aquila I, Cheng HL, Lanzoni L, Asmarats Serra L, Kadrabulatova S, Ranjbar S, Szczesniak-Stanczyk D, Sharka I, Di Salvo G, Ben Kahla S, Li L, Hadeed HA, Habeeb HA, Toscano A, Granata F, Djikic D, Wdowiak-Okrojek K, Girgis HYA, Sharma A, Soro C, Gallego Page JC, Corneli M, Teixeira R, Roussin I, Lynch M, Muraru D, Romeo G, Ermacora D, Marotta C, Aruta P, Cucchini U, Iliceto S, Martin-Fernandez M, De La Hera Galarza JM, Corros-Vicente C, Colunga Blanco S, Velasco-Alonso E, Leon-Aguero V, Rodriguez-Suarez ML, Moris De La Tassa C, Edwards J, Braim D, Price C, Fraser AG, Salmani F, Arjmand Shabestari A, Szymczyk E, Kupczynska K, Peczek L, Nawrot B, Lipiec P, Kasprzak JD, Driussi C, Ferrara F, Brosolo G, Antonini-Canterin F, Magne J, Aboyans V, Bossone E, Bellucci BM, Fisher JM, Balekian AA, Idapalapati S, Huang F, Wong JI, Tan RS, Teixeira R, Madeira M, Almeida I, Reis L, Siserman A, Dinis P, Dias L, Ramos AP, Goncalves L, Wan FW, Sawaki DS, Dubois-Rande JLDR, Adnot SA, Czibik GC, Derumeaux GD, Ercan G, Tekkesin ILKER, Sahin ST, Cengiz B, Celik G, Demircan S, Aytekin SAIDE, Razvi NA, Nazir SA, Price N, Khan JN, Kanagala P, Singh A, Squire I, Mccann GP, Langel M, Pfeiffer D, Hagendorff A, Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Knapp M, Witkowski M, Musial WJ, Kaminski K, Natali B, D' Anna C, Leonardi B, Secinaro A, Pongiglione G, Rinelli G, Renard S, Michel N, Mancini J, Haentjens J, Sitbon O, Habib G, Imbriaco M, Alcidi G, Santoro C, Buonauro A, Lo Iudice F, Lembo M, Cuocolo A, Trimarco B, Galderisi M, Mora Robles J, Roldan Jimenez MA, Mancisidor MA, De Mora MA, Alnabelsi T, Goykhman I, Koshkelashvili N, Romero-Corral A, Pressman GS, Michalski BW, Kupczynska K, Miskowiec D, Lipiec P, Kasprzak JD, Montoro Lopez N, Refoyo Salicio E, Valbuena Lopez SC, Gonzalez O, Alvarez C, Moreno Yanguela M, Bartha Rasero JL, De La Calle M, Guzman Martinez G, Suarez-Cuenca JA, Merino JA, Gomez Alvarez EB, Delgado LG, Woo YM, Bang WD, Sohn GH, Cheong SS, Yoo SY, Rodriguez Palomares JF, Gutierrez L, Maldonado G, Pineda V, Galian L, Teixido G, Gonzalez Allujas MT, Evangelista A, Garcia Dorado D, Zaremba T, Ekeloef S, Heiberg E, Engblom H, Jensen SE, Sogaard P, Rodriguez Palomares JF, Gutierrez L, Garcia G, Pineda V, Galian L, Teixido G, Gonzalez Allujas MT, Evangelista A, Garcia Dorado D, Dini FL, Galli F, Lattanzi F, Picano E, Marzilli M, Leao S, Moz M, Magalhaes P, Trigo J, Mateus PS, Ferreira A, Moreira JI, De Craene M, Legallois D, Labombarda F, Pellissier A, Sermesant M, Saloux E, Merlo M, Moretti M, Barbati G, Stolfo D, Gigli M, Pinamonti B, Sinagra G, Dores E, Matera A, Innelli P, Innelli P, Lopizzo A, Violini R, Fiorilli R, Cappabianca G, Picano E, Tarsia G, Seo J, Chang HJ, Heo R, Kim IC, Shim CY, Hong GR, Chung N, Melissopoulou MM, Nguyen V, Brochet E, Cimadevilla C, Codogno I, Vahanian A, Messika-Zeitoun D, Pontana F, Vassiliou V, Prasad S, Leclercq C, Samset E, Donal E, Lim DS, Bianchi G, Rossi F, Gianetti J, Marchi F, Cerone E, Nardelli A, Terrazzi M, Solinas M, Maffei S, Pshepiy A, Vasina L, Timofeev E, Reeva S, Zemtsovsky E, Brugger N, Jahren S, De Marchi SF, Seiler C, Jin CN, Tang H, Fan K, Kam K, Yan BP, Yu CM, Lee PW, Reali M, Silvetti E, Salatino T, Mancone M, Pennacchi M, Giordano A, Sardella G, Agati L, Tirado G, Nogales-Romo MT, Marcos-Alberca P, De Agustin A, Almeria C, Rodrigo JL, Garcia Fernandez MA, Macaya C, Perez De Isla L, Mancisidor M, Lara Garcia C, Vivancos R, De Mora M, Petrovic M, Vujisic-Tesic B, Trifunovic D, Boricic-Kostic M, Petrovic I, Draganic G, Petrovic O, Tomic-Dragovic M, Furlan T, Ambrozic J, Mohorko Pleskovic PN, Bunc M, Ribeiras R, Abecasis J, Andrade MJ, Mendes M, Ramakrishnan S, Gupta SK, Juneja R, Kothari SS, Zaleska M, Segiet A, Chwesiuk S, Kroc A, Kosior DA, Andreini D, Solbiati A, Guglielmo M, Mushtaq S, Baggiano A, Beltrama V, Rota C, Guaricci AI, Pepi M, Pons Llinares J, Asmarats Serra L, Pericas Ramis P, Caldes Llull O, Grau Sepulveda A, Frontera G, Vaquer Segui A, Noris M, Bethencourt Gonzalez A, Climent Paya V, Martinez Moreno M, Saura D, Oliva MJ, Sanchez Quinones J, Garcia Honrubia A, Valdes M, De La Morena G, Terricabras M, Costabel JP, Ronderos R, Evangelista A, Venturini C, Galve E, Nemes A, Neubauer S, Rahman Haley S, Banner N, Teixeira R, Caetano F, Almeida I, Trigo J, Botelho A, Silva J, Nascimento J, Goncalves L, Tesic M, Jovanovic I, Petrovic O, Boricic-Kostic M, Dragovic M, Petrovic M, Stepanovic J, Banovic M, Vujisic-Tesic B, Guergelcheva V, Chamova T, Sarafov S, Tournev I, Denchev S, Ikonomidis I, Psarogiannakopoulos P, Tsirigotis P, Paraskevaidis I, Lekakis J, Pelliccia A, Natali BM, Cameli M, Focardi M, Bonifazi M, Mondillo S, Lima C, Assed L, Kalil Filho R, Mady C, Bochi EA, Salemi VMC, Targher G, Valbusa F, Rossi A, Lanzoni L, Lipari P, Zenari L, Molon G, Canali G, Barbieri E, Li L, Craft M, Nanda M, Lorenzo JM, Kutty S, Bombardini T, Sparla S, Di Tommaso C, Losito M, Incampo E, Maccherini M, Mondillo S, Werther Evaldsson A, Radegran G, Stagmo M, Waktare J, Roijer A, Meurling CJ, Hui W, Meijboom FJ, Bijnens B, Dragulescu A, Mertens L, Friedberg MK, Sensoy B, Suleymanoglu M, Akin Y, Sahan E, Sasmaz H, Pasca L, Buzdugan E, Chis B, Stoicescu L, Lynce FC, Smith KL, Mete M, Isaacs C, Viapiana O, Di Nora C, Ognibeni F, Fracassi E, Giollo A, Mazzone C, Faganello G, Di Lenarda A, Rossini M, Galrinho A, Branco L, Timoteo AT, Rodrigues I, Daniel P, Rosa S, Ferreira L, Ferreira R, Polak L, Krauza G, Stokfisz K, Zielinska M, Branco LM, Galrinho A, Mota Carmo M, Teresa Timoteo A, Aguiar Rosa S, Abreu J, Pinto Teixeira P, Viveiros Monteiro A, Cruz Ferreira R, Peeraphatdit T, Chaiteerakij R, Klarich KW, Masia S, Necas J, Nistri S, Negri F, Barbati G, Cioffi G, Russo G, Mazzone C, Faganello G, Pandullo C, Di Lenarda A, Durante A, Rovelli E, Genchi V, Trabattoni L, Zerboni SC, Cattaneo L, Butti E, Ferrari G, Luneva E, Mitrofanova L, Uspensky V, Zemtsovsky E, Kasprzak JD, Rosner S, Karl M, Ott I, Sonne C, Ali Lahmar HM, Hammou L, Forsey J, Gowing L, Miller F, Ramanujam P, Stuart AG, Williams CA, Bandera F, Pellegrino M, Carbone F, Labate V, Alfonzetti E, Guazzi M, Patel NR, Raju P, Beale L, Brickley G, Lloyd GW, Fernandez-Golfin C, Gonzalez A, Rincon LM, Hinojar R, Garcia A, Megias A, Jimenez-Nacher JJ, Moya JL, Zamorano JL, Molon G, Canali G, Bonapace S, Chiampan A, Albrigi L, Barbieri E, Noris Mora M, Rodriguez Fernandez A, Exposito Pineda C, Grande C, Gonzalez Colino R, Macaya Ten F, Fernandez Vazquez X, Fortuny Frau E, Bethencourt Gonzalez A, Karvandi M, Blaszczyk R, Zarczuk R, Brzozowski W, Janowski M, Wysokinski A, Stanczyk B, Myftiu S, Teferici D, Quka A, Dado E, Djamandi J, Kresto L, Duka A, Kristo A, Balla I, Issa Z, Moiduddin N, Siblini G, Bulbul Z, Abid L, Abid D, Kammoun S, Rush E, Craft M, Goodwin J, Kreikemeier R, Cantinotti M, Kutty S, Zolaly MA, Khoshhal SQ, El-Harbi K, Tarawah A, Al-Hawsawi Z, Al-Mozainy I, Bakhoum SWG, Nabil MN, Elebrashy IN, Chinali M, Albanese S, Carotti A, Iacobelli R, Esposito C, Secinaro A, Moscogiuri G, Pasquini L, Malvezzi Caracciolo M, Bianchi RM, Caso P, Arenga F, Riegler L, Scarafile R, D'andrea A, Russo MG, Calabro' P, Simic DS, Peric VP, Mujovic NM, Marinkovic MM, Jankovic NJ, Shim A, Wejner-Mik P, Kasprzak JD, Lipiec P, Jain N, Kharwar R, Saran RK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Pradhan A, Safal S, Marchetti MF, Cacace C, Congia M, Nissardi V, Ruscazio M, Meloni L, Montisci R, Gallego Sanchez G, Calero S, Portero JJ, Tercero A, Garcia JC, Barambio M, Martinez Lazaro R, Meretta AH, Perea GO, Belcastro F, Aguirre E, De Luca I, Henquin R, Masoli O. Poster session 2THE IMAGING EXAMINATIONP536Appropriate use criteria of transthoracic echocardiography and its clinical impact: a continuous challengeP537Implementation of proprietary plug-ins in the DICOM-based computerized echo reporting system fuels the use of 3D echo and deformation imaging in the clinical routine of a multivendor laboratoryP538Exercise stress echocardiography appropriate use criteria: real-life cases classification ease and agreement among cardiologistsANATOMY AND PHYSIOLOGY OF THE HEART AND GREAT VESSELSP539Functional capacity in older people with normal ejection fraction correlates with left ventricular functional reserve and carotid-femoral pulse wave velocity but not with E/e and augmentation indexP540Survey of competency of practitioners for diagnosis of acute cardiopulmonary diseases manifest on chest x-rayASSESSMENT OF DIAMETERS, VOLUMES AND MASSP541Left atrium remodeling in dialysis patients with normal ejection fractionP542The prediction of postinfarction left ventricular remodeling and the role of of leptin and MCP-1 in regard to the presence of metabolic syndromeP543Ascending aorta and common carotid artery: diameters and stiffness in a group of 584 healthy subjectsAssessments of haemodynamicsP544Alternate echo parameters in patients without estimable RVSPAssessment of systolic functionP545Reduced contractile performance in heart failure with preserved ejection fraction: determination using novel preload-adjusted maximal left ventricular ejection forceP546Left ventricular dimensions and prognosis in acute coronary syndromesP547Time course of myocardial alterations in a murine model of high fat diet: A strain rate imaging studyP548Subclinical left ventricular systolic dysfunction in patients with premature ventricular contractionsP549Global myocardial strain by CMR-based feature tracking (FT) and tagging to predict development of severe left ventricular systolic dysfunction after acute st-elevation myocardial infarctionP550Echocardiographic analysis of left and right ventricular function in patients after mitral valve reconstructionP551The role of regional longitudinal strain assessment in predicting response to cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and left bundle branch blockP552Speckle tracking automatic border detection improves echocardiographic evaluation of right ventricular systolic function in repaired tetralogy of fallot patients: comparison with MRI findingsP553Echocardiography: a reproducible and relevant tool in pah? intermediate results of the multicentric efort echogardiographic substudy (evaluation of prognostic factors and therapeutic targets in pah)Assessment of diastolic functionP554Relationship between left ventricular filling pressures and myocardial fibrosis in patients with uncomplicated arterial hypertensionP555Cardiac rehabilitation improves echocardiographic parameters of diastolic function in patients with ischemic heart diseaseP556Diastolic parameters in the calcified mitral annulusP557Biomarkers and echocardiography - combined weapon to diagnose and prognose heart failure with and without preserved ejection fractionP558Diastolic function changes of the maternal heart in twin and singleton pregnancyIschemic heart diseaseP559Syntax score as predictor for the correlation between epicardial adipose tissue and the severity of coronary lesions in patients with significant coronary diseaseP560Impact of strain analysis in ergonovine stress echocardiography for diagnosis vasospastic anginaP561Cardiac magnetic resonance tissue tracking: a novel method to predict infarct transmurality in acute myocardial infarctionP562Infarct size is correlated to global longitudinal strain but not left ventricular ejection fraction in the early stage of acute myocardial infarctionP563Magnetic resonance myocardial deformation assessment with tissue tracking and risk stratification in acute myocardial infarction patientsP564Increase in regional end-diastolic wall thickness by transthoracic echocardiography as a biomarker of successful reperfusion in anterior ST elevation acute myocardial infarctionP565Mitral regurgitation is associated with worse long-term prognosis in ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionP566Statistical significance of 3D motion and deformation indexes for the analysis of LAD infarctionHeart valve DiseasesP567Paradoxical low gradient aortic stenosis: echocardiographic progression from moderate to severe diseaseP568The beneficial effects of TAVI in mitral insufficiencyP569Impact of thoracic aortic calcification on the left ventricular hypertrophy and its regression after aortic valve replacement in patients with severe aortic stenosisP570Additional value of exercise-stress echocardiography in asymptomatic patients with aortic valve stenosisP571Valvulo-arterial impedance in severe aortic stenosis: a dual imaging modalities studyP572Left ventricular mechanics: novel tools to evaluate left ventricular performance in patients with aortic stenosisP573Comparison of long-term outcome after percutaneous mitral valvuloplasty versus mitral valve replacement in moderate to severe mitral stenosis with left ventricular dysfunctionP574Incidence of de novo left ventricular dysfunction in patient treated with aortic valve replacement for severe aortic regurgitationP575Transforming growth factor-beta dependant progression of the mitral valve prolapseP576Quantification of mitral regurgitation with multiple jets: in vitro validation of three-dimensional PISA techniqueP577Impaired pre-systolic contraction and saddle-shape deepening of mitral annulus contributes to atrial functional regurgitation: a three-dimensional echocardiographic studyP578Incidence and determinants of left ventricular (lv) reverse remodeling after MitraClip implantation in patients with moderate-to severe or severe mitral regurgitation and reduced lv ejection fractionP579Severe functional tricuspid regurgitation in rheumatic heart valve disease. New insights from 3D transthoracic echocardiographyP58015 years of evolution of the etiologic profile for prosthetic heart valve replacement through an echocardiography laboratoryP581The role of echocardiography in the differential diagnosis of prolonged fever of unknown originP582Predictive value for paravalvular regurgitation of 3-dimensional anatomic aortic annulus shape assessed by multidetector computed tomography post-transcatheter aortic valve replacementP583The significance and advantages of echo and CT imaging & measurement at transcatherter aortic valve implantation through the left common carotid accessP584Comparison of the self-expandable Medtronic CoreValve versus the balloon-expandable Edwards SAPIEN bioprostheses in high-risk patients undergoing transfemoral aortic valve implantationP585The impact of transcatheter aortic valve implantation on mitral regurgitation severityP586Echocardiographic follow up of children with valvular lesions secondary to rheumatic heart disease: Data from a prospective registryP587Valvular heart disease and different circadian blood pressure profilesCardiomyopathiesP588Comparison of transthoracic echocardiography versus cardiac magnetic for implantable cardioverter defibrillator therapy in primary prevention strategy dilated cardiomyopathy patientsP589Incidence and prognostic significance of left ventricle reverse remodeling in a cohort of patients with idiopathic dilated cardiomyopathyP590Early evaluation of diastolic function in fabry diseaseP591Echocardiographic predictors of atrial fibrillation development in hypertrophic cardiomyopathyP592Altered Torsion mechanics in patients with hypertrophic cardiomyopathy: LVOT-obstruction is the topdog?P593Prevention of sudden cardiac death in hypertrophic cardiomyopathy: what has changed in the guidelines?P594Coronary microcirculatory function as determinator of longitudinal systolic left ventricular function in hypertrophic cardiomyopathyP595Detection of subclinical myocardial dysfunction by tissue Doppler ehocardiography in patients with muscular dystrophiesP596Speckle tracking myocardial deformation analysis and three dimensional echocardiography for early detection of chemotherapy induced cardiac dysfunction in bone marrow transplantation patientsP597Left ventricular non compaction or hypertrabeculation: distinguishing between physiology and pathology in top-level athletesP598Role of multi modality imaging in familiar screening of Danon diseaseP599Early impairment of global longitudinal left ventricular systolic function independently predicts incident atrial fibrillation in type 2 diabetes mellitusP600Fetal cardiovascular programming in maternal diabetes mellitus and obesity: insights from deformation imagingP601Longitudinal strain stress echo evaluation of aged marginal donor hearts: feasibility in the Adonhers project.P602Echocardiographic evaluation of left ventricular size and function following heart transplantation - Gender mattersSystemic diseases and other conditionsP603The impact of septal kinetics on adverse ventricular-ventricular interactions in pulmonary stenosis and pulmonary arterial hypertensionP604Improvement in right ventricular mechanics after inhalation of iloprost in pulmonary hypertensionP605Does the treatment of patients with metabolic syndrome correct the right ventricular diastolic dysfunction?P606Predictors of altered cardiac function in breast cancer survivors who were treated with anthracycline-based therapyP607Prevalence and factors related to left ventricular systolic dysfunction in asymptomatic patients with rheumatoid arthritis: a prospective tissue-doppler echocardiography studyP608Diastolic and systolic left ventricle dysfunction presenting different prognostic implications in cardiac amyloidosisP609Diagnostic accuracy of Bedside Lung Ultrasonography in Emergency (BLUE) protocol for the diagnosis of pulmonary embolismP610Right ventricular systolic dysfunction and its incidence in breast cancer patients submitted to anthracycline therapyP611Right ventricular dysfunction is an independent predictor of survival among cirrhotic patients undergoing liver transplantCongenital heart diseaseP612Hypoplasia or absence of posterior leaflet: a rare congenital anomaly of the mitral valveP613ECHO screening for Barlow disease in proband's relativesDiseases of the aortaP614Aortic size distribution and prognosis in an unselected population of patients referred for standard transthoracic echocardiographyP615Abdominal aorta aneurysm ultrasonographic screening in a large cohort of asympromatic volounteers in an Italian urban settingP616Thoracic aortic aneurysm and left ventricular systolic functionStress echocardiographyP617Wall motion score index, systolic mitral annulus velocity and left ventricular mass predicted global longitudinal systolic strain in 238 patients examined by stress echocardiographyP618Prognostic parameters of exercise-induced severe mitral valve regurgitation and exercise-induced systolic pulmonary hypertensionP619Risk stratification after myocardial infarction: prognostic value of dobutamine stress echocardiographyP620relationship between LV and RV myocardial contractile reserve and metabolic parameters during incremental exercise and recovery in healthy children using 2-D strain analysisP621Increased peripheral extraction as a mechanism compensatory to reduced cardiac output in high risk heart failure patients with group 2 pulmonary hypertension and exercise oscillatory ventilationP622Can exercise induced changes in cardiac synchrony predict response to CRT?Transesophageal echocardiographyP623Fully-automated software for mitral valve assessment in chronic mitral regurgitation by three-dimensional transesophageal echocardiographyP624Real-time 3D transesophageal echocardiography provides more accurate orifice measurement in percutaneous transcatheter left atrial appendage closureP625Percutaneous closure of left atrial appendage: experience of 36 casesReal-time three-dimensional TEEP626Real-time three-dimensional transesophageal echocardiography during pulmonary vein cryoballoon ablation for atrial fibrilationP627Three dimensional ultrasound anatomy of intact mitral valve and in the case of type 2 disfunctionTissue Doppler and speckle trackingP629Left ventricle wall motion tracking from echocardiographic images by a non-rigid image registrationP630The first experience with the new prototype of a robotic system for remote echocardiographyP631Non-invasive PCWP influence on a loop diuretics regimen monitoring model in ADHF patients.P632Normal range of left ventricular strain, dimensions and ejection fraction using three-dimensional speckle-tracking echocardiography in neonatesP633Circumferential ascending aortic strain: new parameter in the assessment of arterial stiffness in systemic hypertensionP634Aortic vascular properties in pediatric osteogenesis imperfecta: a two-dimensional echocardiography derived aortic strain studyP635Assessment of cardiac functions in children with sickle cell anemia: doppler tissue imaging studyP636Assessment of left ventricular function in type 1 diabetes mellitus patients by two-dimensional speckle tracking echocardiography: relation to duration and control of diabetesP637A study of left ventricular torsion in l-loop ventricles using speckle-tracking echocardiographyP638Despite No-Reflow, global and regional longitudinal strains assessed by two-dimensional speckle tracking echocardiography are predictive indexes of left ventricular remodeling in patients with STEMIP639The function of reservoir of the left atrium in patients with medicaly treated arterial hypertensionP640The usefulness of speckle tracking analysis for predicting the recovery of regional systolic function after myocardial infarctionP641Two dimensional speckle tracking echocardiography in assessment of left ventricular systolic function in patients with rheumatic severe mitral regurgitation and normal ejection fractionP642The prediction of left-main and tripple vessel coronary artery disease by tissue doppler based longitudinal strain and strain rate imagingP643Role of speckle tracking in predicting arrhythmic risk and occurrence of appropriate implantable defibrillator Intervention in patients with ischemic and non-ischemic cardiomyopathyComputed Tomography & Nuclear CardiologyP644Cardiac adrenergic activity in patients with nonischemic dilated cardiomyopathy. Correlation with echocardiographyP645Different vascular territories and myocardial ischemia, there is a gradient of association? Eur Heart J Cardiovasc Imaging 2015. [DOI: 10.1093/ehjci/jev278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Quintero-Aldana G, Jorge M, Grande C, Salgado M, Gallardo E, Varela S, López C, Villanueva MJ, Fernández A, Alvarez E, González P, Castellanos J, Casal J, López R, Campos Balea B. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemother Pharmacol 2015; 76:731-7. [PMID: 26242221 DOI: 10.1007/s00280-015-2839-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Accepted: 07/27/2015] [Indexed: 11/30/2022]
Abstract
PURPOSE Previous studies have shown that docetaxel and cisplatin, as single agents, are effective and relatively well tolerated in patients with advanced gastric cancer. The aim of this study was to assess efficacy and toxicity of a biweekly regimen of docetaxel plus cisplatin in patients with advanced gastric cancer. PATIENTS/METHODS Fifty-five patients with histologically proven advanced gastric cancer with at least 1 measurable lesion and ECOG PS ≤ 2 were enrolled. Patients received docetaxel 50 mg/m(2) and cisplatin 50 mg/m(2) every 2 weeks until progression disease, unbearable toxicity or a maximum of 12 cycles. RESULTS In total, 426 cycles were administered (median 8.5 cycles) to 52 evaluable patients. One patient (1.9 %) showed a complete response, while 21 (40.4 %) had partial responses. The objective response rate was 42.3 % (95 % CI 28.9-55.7), the median time to progression was 5.5 months (95 % CI 4.0-7.0), and the median overall survival was 8.9 months (95 % CI 6.0-11.9). The most common grade 3-4 toxicities per cycle were haematological [neutropenia (5.9 %)]. CONCLUSIONS Biweekly administration of docetaxel and cisplatin in advanced gastric cancer has a manageable toxicity profile and shows a promising antitumour activity as a first-line therapy.
Collapse
Affiliation(s)
| | - M Jorge
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - C Grande
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - M Salgado
- Complejo Hospitalario de Ourense, CHOU, Ourense, Spain
| | - E Gallardo
- Complejo Hospitalario Universitario de Santiago, CHUS, Santiago de Compostela, Spain
| | - S Varela
- Hospital Universitario Lucus, Augusti, Lugo, Spain
| | - C López
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - M J Villanueva
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - A Fernández
- Complejo Hospitalario de Ourense, CHOU, Ourense, Spain.
| | - E Alvarez
- Hospital Universitario Lucus, Augusti, Lugo, Spain
| | - P González
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - J Castellanos
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - J Casal
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - R López
- Complejo Hospitalario Universitario de Santiago, CHUS, Santiago de Compostela, Spain
| | | |
Collapse
|
23
|
De La Fuente A, González G, García Carbonero I, García Frade J, Munarriz J, Aguiar Bujanda D, Cuevas B, Cuevas M, Aporta R, Barez A, Callejas M, Murias A, Altés A, Salar A, Sánchez-González B, Grande C, García Marco J, López Á, Moran M, Briones Meijide J. Real World Experience with Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Results from the Spanish Experience. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu339.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Barquiel B, Herranz L, Grande C, Castro-Dufourny I, Llaro M, Parra P, Burgos MA, Pallardo LF. Body weight, weight gain and hyperglycaemia are associated with hypertensive disorders of pregnancy in women with gestational diabetes. Diabetes Metab 2014; 40:204-10. [PMID: 24503192 DOI: 10.1016/j.diabet.2013.12.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Revised: 12/14/2013] [Accepted: 12/24/2013] [Indexed: 10/25/2022]
Abstract
AIM The aim of this study was to measure the capacity of glucose- and weight-related parameters to predict pregnancy-induced hypertensive disorders in women with gestational diabetes. METHODS An observational study was conducted involving 2037 women with gestational diabetes. The associations of glycaemic and weight-related parameters with pregnancy-induced hypertensive disorders were obtained by univariate and adjusted multivariate analyses. Also, model predictability and attributable predictor risk percentages were calculated, and collinearity and factor interactions examined. RESULTS Multivariate analyses revealed that hypertensive disorders were mainly predicted by average third-trimester glycated haemoglobin (HbA(1c)) levels ≥ 5.9%, by being overweight or obese before pregnancy and by excess gestational weight gain after adjusting for age, tobacco use, chronic hypertension, parity, urinary tract infections and gestational age at delivery. Prepregnancy body weight (overweight and obesity) had the strongest impact on pregnancy-related hypertensive disorders (attributable risk percentages were 51.5% and 88.8%, respectively). The effect of being overweight or obese on hypertensive disorders was enhanced by HbA(1c) levels and gestational weight gain, with elevated HbA(1c) levels multiplying the effect of being overweight before pregnancy. CONCLUSION The average third-trimester HbA1c level is a novel risk factor for pregnancy-induced hypertensive disorders in women with gestational diabetes. HbA(1c) levels ≥ 5.9%, prepregnancy overweight or obesity and excess gestational weight gain are all independent risk factors of pregnancy-related hypertensive disorders in such women. In treated gestational diabetes patients, the strongest influence on hypertensive disorders is prepregnancy obesity.
Collapse
Affiliation(s)
- B Barquiel
- Unidad de Diabetes, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
| | - L Herranz
- Unidad de Diabetes, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| | - C Grande
- Servicio de Bioquímica, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| | - I Castro-Dufourny
- Unidad de Diabetes, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| | - M Llaro
- Unidad de Diabetes, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| | - P Parra
- Unidad de Diabetes, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| | - M A Burgos
- Servicio de Ginecología y Obstetricia, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| | - L F Pallardo
- Unidad de Diabetes, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
| |
Collapse
|
25
|
Abstract
Obestatin is a 23 amino acid peptide encoded by the ghrelin gene, which, like ghrelin, is mainly produced by the stomach, as well as by a wide range of other tissues. Obestatin remains a controversial peptide, as the initial finding of its binding to the orphan receptor GPR39 and the inhibitory effect on food intake has been questioned. In fact, to date, its biological effects are still largely unknown, although it is becoming clear that obestatin is a pleiotropic hormone, exerting a variety of effects in different cell types and tissues. Indeed, besides regulating cell proliferation and survival, obestatin has been shown to regulate glucose and lipid metabolism, both in vitro, in pancreatic β-cells and adipocytes, and in vivo in rodents. Furthermore, its positive effects on glucose homeostasis, combined with the anti-inflammatory actions, make this peptide appealing as a candidate for treating metabolic disorders such as insulin resistance and diabetes.
Collapse
Affiliation(s)
- E Gargantini
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Torino, Torino, Italy
| | - C Grande
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Torino, Torino, Italy
| | - L Trovato
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Torino, Torino, Italy
| | - E Ghigo
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Torino, Torino, Italy
| | - R Granata
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Torino, Torino, Italy
| |
Collapse
|
26
|
Balbi T, Fabbri R, Cortese K, Smerilli A, Ciacci C, Grande C, Vezzulli L, Pruzzo C, Canesi L. Interactions between Mytilus galloprovincialis hemocytes and the bivalve pathogens Vibrio aestuarianus 01/032 and Vibrio splendidus LGP32. Fish Shellfish Immunol 2013; 35:1906-1915. [PMID: 24080469 DOI: 10.1016/j.fsi.2013.09.027] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Revised: 09/16/2013] [Accepted: 09/19/2013] [Indexed: 06/02/2023]
Abstract
Marine bivalves can accumulate large numbers of bacteria, in particular Vibrio species, whose persistence in bivalve tissues largely depends on their sensitivity to the bactericidal activity of circulating hemocytes and hemolymph soluble factors. The interactions between vibrios and hemolymph have been investigated, in particular in bivalve species susceptible to infection by certain Vibrio spp. and strains. In this work, the effects of two bivalve pathogens, Vibrio splendidus LGP32 (V.s.) and Vibrio aestuarianus 01/032 (V.a.), isolated from oyster mortality outbreaks, on the hemocytes of Mytilus galloprovincialis were investigated. In vitro, V.s., but not V.a., induced a dramatic decrease in lysosomal membrane stability-LMS in the hemocytes; both vibrios induced a moderate lysozyme release, with V.s. > V.a.. The V.s.-induced decrease in LMS was mediated by activation of PI-3Kinase, as shown by use of different kinase inhibitors. TEM analysis showed rapid internalization of both vibrios; however, V.s. lead to cellular and lysosomal damage and was able to survive within the hemocytes, whereas significant killing of V.a. was observed. In vivo, in mussels challenged with either vibrio and sampled at 6, 24 and 96 h post-injection, transient decreases in hemocyte LMS and progressive increases in serum lysozyme activity were observed, with V.s. > V.a.. Moreover, whereas V.a. was efficiently cleared from hemolymph, V.s. showed significant growth, that was maximal at 24 h p.i. when lowest LMS values were recorded in the hemocytes. Both vibrios also induced significant decreases in LMS in the digestive gland, again with V.s. > V.a.. The results indicate distinct interactions between mussel hemocytes and the two vibrio strains tested. The effects of V.s. may be due to the capacity of this strain to interfere with the signaling pathways involved in hemocyte function, thus escaping the bactericidal activity of the host cell, as observed for certain mammalian pathogens. Although V.s. is considered not pathogenic to Mytilus, this vibrio strain can affect the lysosomal function at the cellular and tissue level, thus leading to stressful conditions.
Collapse
Affiliation(s)
- T Balbi
- DISTAV, Dipartimento di Scienze della Terra, dell'Ambiente e della Vita, Università di Genova, Corso Europa 26, 16132 Genova, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Chimenti C, Scopelliti F, Verardo R, Grande C, Fedele F, Frustaci A. Toll-like receptor 4 is a marker of immune-mediated damage in patients with inflammatory cardiomyopathy. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p3865] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Frustaci A, Verardo R, Scopelliti F, Francone M, Grande C, Badagliacca R, Vizza D, Fedele F, Petrosillo N, Chimenti C. Myocardial and micro-vascular inflammation/infection in HIV/HCV associated pulmonary artery hypertension. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Parrondo J, Grande C, Ibáñez J, Palau J, Páramo JA, Villa G. [Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia]. Farm Hosp 2013; 37:182-91. [PMID: 23789796 DOI: 10.7399/fh.2013.37.3.526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To develop a tool to assist the decision-making for selection of Thrombopoyetin Receptor Agonists of adult patients with chronic immune primary thrombocytopenia (PTI). METHODS Stochastic cost-effectiveness analysis with a 6-Health- States Markov model: stable, bleeding type 2, 3 or 4, post-type 4 bleeding and death. Each simulation analyzes a randomly generated scenario that describes patients characteristics, results measured in quality adjusted life years (QALYs) and costs (in ?2011). Distributions were obtained from the Spanish data of the European health survey of 2009, the INE estimate of population for 2011 and the 6-months clinical studies for Eltrombopag and Romiplostim. Utility values were obtained from the literature and the costs from Spanish official rates lists. A set of 10.000 random scenarios were generated and the patients evolution of each scenario was simulated during a time horizon of five years (in 2-weeks cycles). National Health System Perspective was used and the annual discount rate was set at 3%. RESULTS Eltrombopag showed more effectiveness in 9.983 scenarios and there was no difference in 17. In 7.048 scenarios the alternative Eltombopag was dominant. It was cost-effective in another 19 (threshold 30,000 ??/AVAC). CONCLUSIONS Eltrombopag was the most cost-effective alternative in 70,67% of the simulated scenarios and its use could produce lower costs to the NHS.
Collapse
MESH Headings
- Administration, Oral
- Adult
- Benzoates/adverse effects
- Benzoates/economics
- Benzoates/therapeutic use
- Combined Modality Therapy
- Computer Simulation
- Cost Savings
- Cost-Benefit Analysis
- Drug Costs/statistics & numerical data
- Female
- Hemorrhage/economics
- Hemorrhage/etiology
- Hemorrhage/prevention & control
- Humans
- Hydrazines/adverse effects
- Hydrazines/economics
- Hydrazines/therapeutic use
- Injections, Subcutaneous
- Male
- Markov Chains
- Middle Aged
- Models, Economic
- National Health Programs/economics
- Purpura, Thrombocytopenic, Idiopathic/drug therapy
- Purpura, Thrombocytopenic, Idiopathic/economics
- Purpura, Thrombocytopenic, Idiopathic/epidemiology
- Purpura, Thrombocytopenic, Idiopathic/surgery
- Pyrazoles/adverse effects
- Pyrazoles/economics
- Pyrazoles/therapeutic use
- Receptors, Fc/therapeutic use
- Receptors, Thrombopoietin/agonists
- Recombinant Fusion Proteins/adverse effects
- Recombinant Fusion Proteins/economics
- Recombinant Fusion Proteins/therapeutic use
- Severity of Illness Index
- Spain
- Splenectomy
- Stochastic Processes
- Thrombopoietin/adverse effects
- Thrombopoietin/economics
- Thrombopoietin/therapeutic use
- Time Factors
Collapse
|
30
|
Grande C, Medina M, Martinez M, Willisch P, Huidobro G, Vazquez M, Villanueva M, Muñoz V, Casal J. Flox as adjuvant treatment after chemo-radiotherapy and surgery in rectal cancer. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
31
|
Caeiro M, Gomez A, Casal J, Leiva R, Lazaro M, Vazquez S, Pena C, Grande C, Carballo A. Prophylactic cranial irradiation (PCI) in non small cell lung cancer (NSCLC). Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
32
|
Egeler O, Grande C, Yuan N, Wognum B, Woodside S, Booth A, Szilvassy S, Thomas T, Eaves A. Stemvision™: a bench-top instrument for auto-mated and standardized counting of all hematopoietic colony types in CFU assays of human bone marrow, cord blood and mobilized peripheral blood cells. Cytotherapy 2013. [DOI: 10.1016/j.jcyt.2013.01.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Agatone S, Facco P, Grande C, Iorio A, Leggiero A, Fiori M, Capogna S, Santini A, Giovannini M. M141 IUD INSERTION FOLLOWING INDUCED ABORTION. Int J Gynaecol Obstet 2012. [DOI: 10.1016/s0020-7292(12)61335-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Bianchi E, Scarinci F, Grande C, Plateroti R, Plateroti P, Plateroti A, Fumagalli L, Capozzi P, Feher J, Artico M. Immunohistochemical Profile and VEGF, TGF-β and PGE2 in Human Pterygium and Normal Conjunctiva: Experimental Study and Review of the Literature. Int J Immunopathol Pharmacol 2012; 25:607-15. [PMID: 23058011 DOI: 10.1177/039463201202500307] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Human pterygium is made up of chronic proliferative fibro-vascular tissue growing on the ocular surface. This disease exhibits both degenerative and hyperplastic properties. Some fibroangiogenic factors have recently been shown to play a potential role in fibrovascular diseases via the angiogenesis process. The aim of this study is to evaluate VEGF, TGF-β and PGE2 expression in the epithelial, endothelial and stromal cells of human pterygium and normal conjunctiva in order to determine whether these factors participate in the development of pterygium. Ten specimens from patients with pterygium and two normal conjunctivas (cadavers) were analyzed by immunohistochemistry using specific antibodies against these growth factors. The technique used was ABC/HRP (Avidin complexed with biotinylated peroxidase). Immunoreactivity of VEGF was significantly increased in the epithelium, vascular endothelium and stromal cells in primary pterygium as compared with normal conjunctiva. A moderate expression of TGF-β in the pterygium was observed in the epithelial and stromal layers. On the contrary, immunolabeling of this growth factor in the human normal conjunctiva was weak. PGE2 was strongly expressed in the epithelium of patients with pterygium, as in control conjunctival tissues, and the immunolabeling was moderate in the stroma from the same patients. Our results suggest that these growth factors may contribute to the progression of primary pterygium by increasing angiogenesis, thus leading to the formation of new blood vessels from the pre-existing vasculature. We conclude that VEGF, TGF-β and PGE2 may be potential therapeutic targets in the treatment of this disease although proof of this evidence requires further studies.
Collapse
Affiliation(s)
- E. Bianchi
- Department of Sensory Organs, Rome, Italy
| | - F. Scarinci
- G.B. Bietti Eye Foundation-IRCCS, Rome, Italy
| | - C. Grande
- Department of Sensory Organs, Rome, Italy
| | | | | | | | - L. Fumagalli
- Department of Anatomical, Histological, Medico-legal and Locomotor System Sciences, University of Rome ‘Sapienza’, Rome, Italy
| | - P. Capozzi
- Bambino Gesù Children's Hospital IRCCS, Ophthalmic Department Rome, Italy
| | - J. Feher
- Department of Sensory Organs, Rome, Italy
- Ophthalmic Neuroscience Program, Rome, Italy
| | - M. Artico
- Department of Sensory Organs, Rome, Italy
| |
Collapse
|
35
|
Glasmeyer P, Grande C, Margarit J, Martí M, Torino JR, Mirada A, Sans A. [Gastroschisis. Preterm elective cesarean and immediate primary closure: our experience]. Cir Pediatr 2012; 25:12-15. [PMID: 23113406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
PURPOSE Our experience en treatment of gastroschisis using a protocol with elective preterm delivery by caesarean section at 34-35 weeks and immediate primary abdominal wall closure. METHODS During a period of 18 month we treated 5 patients with gastroschisis using the following management pathway: Starting at 30th week of gestation, weekly ultrasound evaluation of fetal gut and pulmonary maturation with corticosteroids. Delivery by elective caesarean section between 34-35 weeks or earlier if evidence of bowel compromise was reported en ultrasound study. Immediate surgical correction after birth with primary closure was preformed under control of abdominal pressure. RESULTS Mean gestational age of our patient was 33,94 weeks, and mean birth weight was 2154 gr. None of the cases present inflammatory peel and we found no difficulties for reduction of the gut at time of surgery. Two patients presented an intestinal malrotation. Extubation was preformed 36-48 hours after surgery. We started a trofic diet at 3,6 days and parental nutrition was retired after a mean period of 15,8 days. The mean time of hospital stay was 33,4 days. One patient with intestinal obstruction had a consideriously increased length of hospital stay of 74 days. CONCLUSIONS A management pathway for gastroschisis with selective preterm delivery by caesarean section and immediate surgical treatment probably reduces the experience of inflammatory peel. This pathway permits a early initiation of oral feeding, reduces times of parenteral nutrition and need of central catheters, and shortens length of hospital stay.
Collapse
Affiliation(s)
- P Glasmeyer
- Servicio de Cirugía Pediátrica, Hospital Mútua de Terrassa.
| | | | | | | | | | | | | |
Collapse
|
36
|
Lázaro M, Varela S, Vazquez S, Villanueva M, Firvida J, Amenedo M, Afonso F, Senin C, Grande C. 9099 POSTER Biweekly Docetaxel-Cisplatin in Chemonaive Patients With Advanced Epidermoid Carcinoma of the Lung – a Phase II Study of Galician Lung Cancer Group. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72411-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Iyer R, Fetterly G, Groman A, Hutson A, Khushalani N, Mohile S, Ashton E, Litwin A, Grande C, Tomaszewski G. 6517 POSTER Sunitinib and Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma (HCC)- Final Results of a Phase 2 Trial. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71828-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
38
|
Vázquez S, Villanueva M, Firvida J, Lázaro M, Campos B, Grande C, Fernandez A, Varela S, Casal J, Perez E. 9085 POSTER Gemcitabine Plus Oral Vinorelbine as Salvage Therapy Treatment for Patients With Advanced Non-small-cell Lung Cancer and Squamous Histology – a Gallclan Lung Cancer Group Study (GGCP042/09) Grupo Galego De Cancro De Pulmon (GGCP). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72397-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
39
|
Grande C, Martinez M, Villanueva M, Huidobro G, Casal J. 6592 POSTER 5-Fluorouracil/Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) as First-Line Treatment of Advanced Gastric Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71903-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010; 103:1536-41. [PMID: 20940719 PMCID: PMC2990582 DOI: 10.1038/sj.bjc.6605938] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Combination of bevacizumab and FOLFIRI has currently become one of the standard therapeutic regimens. However, published information is still limited. The objective of the present retrospective observational study is to analyse the response and toxicity of first-line treatment with FOLFIRI+bevacizumab in patients with metastatic colorectal cancer (mCRC). METHODS Data were collected from patients from nine Spanish sites diagnosed with mCRC, ECOG≤2, whose first treatment for advanced disease was at least three cycles of FOLFIRI+bevacizumab. RESULTS A total of 95 patients were enrolled into the study: 64.2% males, median age of 59 years (53.2-67.1 years), ECOG=0-1 in 96.9% of patients. The main site of primary tumour was the colon (69.7%), and most metastases occurred in the liver (71.6%). Clinical benefit was detected in 67.4% (57.0-76.6; 95% confidence interval (CI)), with 8.4% of CR and 42.1% of PR. Median TTP was 10.6 months (10.0-11.3; 95% CI), PFS was 10.6 months (9.8-11.3; 95% CI), and OS was 20.7 months (17.1-24.2; 95% CI). Main grade I-II toxicities included haematological toxicity (35.8%), diarrhea (27.3%), mucositis (25.3%), asthenia (19.0%), haemorrhages (11.6%), and emesis (10.6%). Toxicities reaching grades III-IV were haematological toxicity (9.5%), diarrhea (8.5%), mucositis (5.3%), hepatic toxicity (2.1%), asthenia (2.1%), proteinuria (1.1%), emesis (1.1%), pain (1.1%), and colics (1.1%). CONCLUSION Results of this study support the beneficial effect of adding bevacizumab to FOLFIRI regimen in terms of efficacy and show a favourable tolerability profile.
Collapse
Affiliation(s)
- R López
- Department of Oncology, Complejo Hospitalario Universitario de Santiago, Travesía da Choupana, s/n, 15706 Santiago de Compostela, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Grande C, Patel NH. Lophotrochozoa get into the game: the nodal pathway and left/right asymmetry in bilateria. Cold Spring Harb Symp Quant Biol 2010; 74:281-287. [PMID: 20413706 DOI: 10.1101/sqb.2009.74.044] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Animals as diverse as humans, flies, crabs, and snails show overall bilateral symmetry, but each species has specific structures and organs that display left/right asymmetry, and the presence of these asymmetries is vital to the organism. Here, we review recent results showing that part of the molecular pathway that sets left/right asymmetry in vertebrates is also conserved in snails, suggesting that left/right asymmetry was present in the common ancestor of all bilaterians. More specifically, we can now predict that the signaling molecule Nodal and the transcription factor Pitx were expressed on the right side of the bilaterian ancestor. These results also allow us to understand how the direction of shell coiling (chirality) is regulated in snails and provides interesting insights into the possible inversion of the dorsoventral axis in the lineage leading to chordates.
Collapse
Affiliation(s)
- C Grande
- Centro de Biología Molecular Severo Ochoa. Universidad Autónoma de Madrid. 28049, Madrid, Spain
| | | |
Collapse
|
43
|
Artico M, Bronzetti E, Alicino V, Ionta B, Bosco S, Grande C, Bruno M, Tranquilli Leali FM, Ionta G, Fumagalli L. Human gallbladder carcinoma: Role of neurotrophins, MIB-1, CD34 and CA15-3. Eur J Histochem 2010; 54:e10. [PMID: 20353905 PMCID: PMC3167291 DOI: 10.4081/ejh.2010.e10] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2010] [Accepted: 01/28/2010] [Indexed: 12/19/2022] Open
Abstract
Gallbladder carcinoma is the most common biliary tract tumor and the fifth most common gastrointestinal tract cancer. The prognosis of gallbladder carcinoma is poor and less than 5% of the patients are still alive five years postoperatively. Gallbladder specimens were obtained during surgical operations performed in eleven patients for resection of a gallbladder carcinoma, and during five autopsies (control cases selected among patients who died from for other causes, excluding those suffering from biliary or hepatic diseases). Immunohistochemical characterization and distribution of neurotrophins, with their respective receptors, were analyzed. The actual role played by these neurotrophic factors in the general regulation, vascular permeability, algic responsiveness, release of locally active substances and potential tumorigenesis in the gallbladder and biliary ducts compartment remains controversial. Our study revealed an increased immunohistochemical expression of NGF and TrKA in the epithelium and in the epithelial glands of the gallbladder carcinoma together with an evident immunoreactivity for BDNF in the same neoplastic areas. An evident immunoreactivity for NGF, TrKA and BDNF was observed in control specimens of gallbladder obtained during autopsies, whereas a weak or quite absent immunoreactivity was observed in the same specimens for NT4, TrKC and p75. On the contrary an appreciable immunoreactivity for p75 was observed in the specimens harvested from patients with gallbladder carcinoma. We also investigated the expression of some known tumor markers such as MIB-1 (anti Ki-67), CD34 and CA15-3, to identify a possible correlation between the expression of these molecular factors and the prognosis of gallbladder carcinoma. They resulted highly expressed in the stroma (CD34 and CA 15-3) and in the epithelium/epithelial glands (MIB-1) of the neoplastic areas and appeared to be almost absent in the control cases, suggesting that these markers, taken together, could be adopted as a panel of prognostic factors in the evaluation of the gallbladder carcinoma.
Collapse
Affiliation(s)
- M Artico
- Department of Otorhinolaringology, Audiology and Phoniatry G. Ferreri, University of Rome La Sapienza, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Alexandru S, Gonzalez E, Grande C, Hernandez A, Morales E, Praga M, Andres A, Morales J. Monotherapy Rapamycin in Renal Transplant Recipients With Lymphoma Successfully Treated With Rituximab. Transplant Proc 2009; 41:2435-7. [DOI: 10.1016/j.transproceed.2009.05.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
45
|
Grande C, Quintero G, Mel JR, Huidobro G, Campos B, Candamio S, Méndez JC, Salgado M, Álvarez E, Casal J. Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15053 Background: Analysis of efficacy and toxicity of biweekly XELOX as first line monotherapy in elderly patients (pts) with metastatic colorectal cancer (MCRC), based in results of W. Scheithauer (J Clin Oncol 2003; 21: 1307). Methods: From March/06 to November/08, 28 chemonaïve elderly pts (>75 years old) with MCRC, PS: 0–2, and adequate renal, hepatic and bone marrow functions, were included in a phase II study of: oxaliplatin 85 mg/ m2/ day 1 plus capecitabine 2000/ m2/ in 2 divided doses/ days 1–7 every 2 weeks. Treatment was continued until 12 cycles, tumour progression or innaceptable toxicity. Response evaluation every 6 cycles and toxicity every cycle was performed. At present 28 pts for toxicity and 24 pts for response are evaluable. Results: Median age: 78.2 years (range: 73.5–79.5). Male/Female: 14/14. Rectal/Colon: 9/19. Metastatic sites 1/2/>2: 15/6/6. Liver 78.6%, Lung 32.1%, Local tumour 7.1%, Retroperitoneum 14.2%, Peritoneum 10.7%. and Bones 7.1 %. Previous adjuvant with 5-FU regimens to 4 pts. Comorbidity grade by Charlson index 0–1/2/>2: 60.8%/ 28.6% / 10.7%, respectively. Median number of cycles for oxaliplatin and capecitabine were 8 (5.25–12) and 8 (5.25–11.75). Response rate: 2 pts complete response (8.3%), 8 pts partial response (33.3%),10 pts stable disease (41.7 %) and 4 pts progression (16.7%). The main CTC toxicity was Asthenia G2+3 in 6 (21.5%), Nausea and emesis G2 in 7 (25%), Diarrhea G2+3 in 7 (25%) and Hand-foot syndrome G1+2 in 5 pts (17.8%). No G4 toxicity or toxic deaths were observed. Median time to progression was 8.6 months.Median overall survival will be given updated at the congress. Conclusions: Preliminary results suggest that bi-weekly XELOX is an effective first line treatment for MCRC in elderly pts with an acceptable toxicity profile (especial surveillance of diarrhea is necessary) and protocol cumpliment. Combination with bevacizumab should be considered. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Grande
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - G. Quintero
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - J. R. Mel
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - G. Huidobro
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - B. Campos
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - S. Candamio
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - J. C. Méndez
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - M. Salgado
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - E. Álvarez
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| | - J. Casal
- Hospital Meixoeiro del Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Complexo Hospitalario Xeral-Calde, Lugo, Spain; Hospital Meixoeiro del C. H. U. de Vigo, Vigo, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Centro Oncológico de Galicia, La Coruña, Spain; Complejo Hospitalario de Ourense, Orense, Spain
| |
Collapse
|
46
|
Serrano-Navarro I, Rodríguez-López JF, Navas-Espejo R, Pérez-Jacoiste MA, Martínez-González MA, Grande C, Prieto S. [Primary hepatic lymphoma - favorable outcome with chemotherapy plus rituximab]. Rev Esp Enferm Dig 2009; 100:724-8. [PMID: 19159179 DOI: 10.4321/s1130-01082008001100011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
This article describes the case of a patient with a non-Hodgkin primary hepatic lymphoma who was successfully treated with chemotherapy combined with rituximab. Using the Medical Subject Headings the published reports of this rare entity were reviewed.
Collapse
Affiliation(s)
- I Serrano-Navarro
- Servicios de Medicina Interna, Hostpial Universitario 12 de Octubre, Madrid, Espana
| | | | | | | | | | | | | |
Collapse
|
47
|
Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, Garcia-Sanchez P, Vazquez L, Nistal S, Requena MJ, Donato EM, Gonzalez JA, Leon A, Ruiz C, Grande C, Gonzalez-Barca E, Caballero MD. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93:1829-36. [DOI: 10.3324/haematol.13440] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
48
|
Nelson M, Blum DS, Gralow JR, Cardoso F, Grande C, Palmieri FM, Kirk MC, Eagan C. Oncologist and patient roles in assessing current and future treatment for metastatic breast cancer: Results of an observational linguistic study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Vazquez-Estevez S, León L, Fírvida JL, Grande C, Vázquez F, Salgado M, Casal J, Barón FJ, Abal J, García J. Biweekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2: A phase II study of the Galician Lung Cancer Group. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Roca J, Alonso V, Pericay C, Escudero P, Grande C, Vicente P, Arrivi A, Martin C, Moreno I, Garcia A. Cetuximab given every 2 weeks (q2w) plus irinotecan, as feasible option, for previously treated patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|